research use only
Cat.No.S2202
| Related Targets | EGFR VEGFR PDGFR FGFR c-Met Src MEK CSF-1R FLT3 HER2 |
|---|---|
| Other Ephrin receptor Inhibitors | ALW II-41-27 Ehp-inhibitor-1 NVP-BHG712 isomer AWL-II-38.3 |
|
In vitro |
DMSO
: 101 mg/mL
(200.6 mM)
Ethanol : 3 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 503.48 | Formula | C26H20F3N7O |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 940310-85-0 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | CC1=C(C=C(C=C1)C(=O)NC2=CC=CC(=C2)C(F)(F)F)NC3=C4C=NN(C4=NC(=N3)C5=CN=CC=C5)C | ||
| Features |
Discriminates between VEGFR and EphB4.
|
|---|---|
| Targets/IC50/Ki |
EphB4
(cell based assays ) 25 nM(ED50)
C-Raf
(Cell-free assay) 0.395 μM
c-Src
(Cell-free assay) 1.266 μM
c-Abl
(Cell-free assay) 1.667 μM
|
| In vitro |
NVP-BHG712 treatment also dose dependently leads to the inhibition of RTK autophosphorylation in stable transfected A375 melanoma cells with EC50 of 25 nM and 4.2 μM for EphB4 and VEGFR2, respectively.
|
| In vivo |
In a growth factor-induced angiogenesis model, NVP-BHG712 (3 mg/kg, p.o) significantly suppresses VEGF stimulated tissue formation and vascularization by inhibiting EphB4 forward signaling. Furthermore, this compound (10 mg/kg/kg, p.o.) potently reverses VEGF enhanced tissue formation and vessel growth. It (3 mg/kg, p.o.) shows a long lasting exposure with concentrations around 10 μM in plasma as well as in lung and liver tissue for up to 8 hours, and thus results in a long lasting inhibition of EphB4 kinase activity in mice.
|
References |
| Methods | Biomarkers | Images | PMID |
|---|---|---|---|
| Western blot | p-EphB4 / p-EphB2 / p-EphB3 / p-EphA2 / p-EphA3 |
|
20803239 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.